The IBN SINA Pharmaceutical Industry (DHA:IBNSINA) Beginning Cash Position: BDT335 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:IBNSINA The IBN SINA Pharmaceutical Industry PLC DHA:IBNSINA
45 GF Score
Price BDT315.50
GF Value BDT380.73
Valuation Modestly Undervalued
View Full Analysis

What is The IBN SINA Pharmaceutical Industry Beginning Cash Position?

The IBN SINA Pharmaceutical Industry DHA:IBNSINA +1.28% 45 Beginning Cash Position is BDT335 Mil as of Mar. 2026. GuruFocus rates DHA:IBNSINA with a GF Score™ of 45/100 and a GF Value™ of BDT380.73 (Modestly Undervalued).

The IBN SINA Pharmaceutical Industry's Beginning Cash Position for the quarter that ended in Mar. 2026 was BDT335 Mil.

The IBN SINA Pharmaceutical Industry's quarterly Beginning Cash Position increased from Sep. 2025 (BDT315 Mil) to Dec. 2025 (BDT341 Mil) but then declined from Dec. 2025 (BDT341 Mil) to Mar. 2026 (BDT335 Mil).

The IBN SINA Pharmaceutical Industry's annual Beginning Cash Position declined from Jun. 2023 (BDT343 Mil) to Jun. 2024 (BDT232 Mil) but then increased from Jun. 2024 (BDT232 Mil) to Jun. 2025 (BDT365 Mil).

The IBN SINA Pharmaceutical Industry Beginning Cash Position Related Terms

The IBN SINA Pharmaceutical Industry Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for The IBN SINA Pharmaceutical Industry's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The IBN SINA Pharmaceutical Industry Beginning Cash Position Chart

The IBN SINA Pharmaceutical Industry Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 199.91 281.24 342.61 232.23 365.23

The IBN SINA Pharmaceutical Industry Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 280.65 393.78 314.90 340.64 335.24
DHA:IBNSINA
45GF Score
The IBN SINA Pharmaceutical Industry PLC DHA:IBNSINA
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

The IBN SINA Pharmaceutical Industry Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of BDT335 Mil mean?
The IBN SINA Pharmaceutical Industry (DHA:IBNSINA) has a Beginning Cash Position of BDT335 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on The IBN SINA Pharmaceutical Industry and its competitors.
Is The IBN SINA Pharmaceutical Industry's Beginning Cash Position too high?
The IBN SINA Pharmaceutical Industry's current Beginning Cash Position is BDT335 Mil. Overall, The IBN SINA Pharmaceutical Industry has a GF Score™ of 45/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The IBN SINA Pharmaceutical Industry's Beginning Cash Position compare to IMNPQ?
The IBN SINA Pharmaceutical Industry's Beginning Cash Position of BDT335 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Drug Manufacturers company?
A good Beginning Cash Position depends on the Drug Manufacturers industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on The IBN SINA Pharmaceutical Industry and its competitors. The IBN SINA Pharmaceutical Industry's current Beginning Cash Position is BDT335 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The IBN SINA Pharmaceutical Industry stock overvalued right now?
Based on GuruFocus' analysis, The IBN SINA Pharmaceutical Industry (DHA:IBNSINA) is currently considered Modestly Undervalued. The stock's GF Value™ is BDT380.73, compared to a current price of BDT315.50 — trading 17.1% below its estimated fair value. The current Beginning Cash Position is BDT335 Mil. The IBN SINA Pharmaceutical Industry's overall GF Score™ is 45/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For The IBN SINA Pharmaceutical Industry (DHA:IBNSINA), the current Beginning Cash Position is BDT335 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is The IBN SINA Pharmaceutical Industry (DHA:IBNSINA) Overvalued in 2026?

Based on GuruFocus' analysis, The IBN SINA Pharmaceutical Industry stock appears to be undervalued. The current stock price of BDT315.50 is trading 17.1% below its estimated GF Value™ of BDT380.73. GuruFocus considers The IBN SINA Pharmaceutical Industry to be Modestly Undervalued.

Key valuation signals for DHA:IBNSINA:

  • Beginning Cash Position: BDT335 Mil
  • GF Value™: BDT380.73 vs. price of BDT315.50 (17.1% below fair value)
  • GF Score™: 45/100

No single metric tells the full story. See the DHA:IBNSINA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

The IBN SINA Pharmaceutical Industry Business Description

Address Mirpur Road, Tanin Center, 3 Asad Gate, Mohammadpur, Dhaka, BGD, 1207
The IBN SINA Pharmaceutical Industry PLC is engaged in the production and marketing of pharmaceutical drugs and natural medicines in both the local and international market.
45GF Score

Get the complete analysis for DHA:IBNSINA

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT315.50
Price
BDT380.73
GF Value